Christopher C Nessel
Overview
Explore the profile of Christopher C Nessel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
59
Citations
5300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Harrington J, Hellkamp A, Mahaffey K, Breithardt G, Halperin J, Hankey G, et al.
J Am Heart Assoc
. 2024 May;
13(11):e028951.
PMID: 38780169
Background: Days alive out of hospital (DAOH) is an objective and patient-centered net benefit end point. There are no assessments of DAOH in clinical trials of interventions for atrial fibrillation...
2.
Carnicelli A, Hellkamp A, Mahaffey K, Singer D, Breithardt G, Halperin J, et al.
J Am Heart Assoc
. 2021 Sep;
10(19):e022485.
PMID: 34569249
Background In event-driven clinical trials, study termination is based on accrual of a target number of primary efficacy events. For noninferiority trials in which superiority is conditionally examined, the ideal...
3.
Ugowe F, Hellkamp A, Wang A, Becker R, Berkowitz S, Breithardt G, et al.
Heart Rhythm O2
. 2021 Aug;
2(3):215-222.
PMID: 34337571
Background: Insulin use may be a better predictor of stroke risk and morbidity and mortality than diabetes in patients with atrial fibrillation (AF). Objectives: Determine if the increased risk of...
4.
Blumer V, Rivera M, Corbalan R, Becker R, Berkowitz S, Breithardt G, et al.
Am Heart J
. 2021 Feb;
236:4-12.
PMID: 33571477
Background: ROCKET AF demonstrated the efficacy and safety of rivaroxaban compared with warfarin for the prevention of stroke and systemic embolism (SE) in patients with atrial fibrillation (AF). We examined...
5.
Ungar L, Rodriguez F, Hellkamp A, Becker R, Berkowitz S, Breithardt G, et al.
Cardiol Ther
. 2019 Aug;
8(2):283-295.
PMID: 31376090
Introduction: Patient-reported outcomes (PROs) and satisfaction endpoints are increasingly important in clinical trials and may be associated with treatment adherence. In this post hoc substudy from ROCKET AF, we examined...
6.
Greenberg B, Neaton J, Anker S, Byra W, Cleland J, Deng H, et al.
JAMA Cardiol
. 2019 Apr;
4(6):515-523.
PMID: 31017637
Importance: Whether anticoagulation benefits patients with heart failure (HF) in sinus rhythm is uncertain. The COMMANDER HF randomized clinical trial evaluated the effects of adding low-dose rivaroxaban to antiplatelet therapy...
7.
Quinn G, Hellkamp A, Hankey G, Becker R, Berkowitz S, Breithardt G, et al.
J Am Heart Assoc
. 2018 Oct;
7(15):e008755.
PMID: 30371223
Background There is concern that selective serotonin reuptake inhibitors ( SSRI s) substantially increase bleeding risk in patients taking anticoagulants. Methods and Results We studied 737 patients taking SSRI s...
8.
Chen S, Hellkamp A, Becker R, Berkowitz S, Breithardt G, Fox K, et al.
Eur Heart J Qual Care Clin Outcomes
. 2018 Sep;
5(2):145-152.
PMID: 30219887
Aims: The management of anticoagulation therapy in patients with atrial fibrillation (AF) and cancer is challenging due to increased thrombotic and bleeding risks. We sought to determine the safety and...
9.
Zannad F, Anker S, Byra W, Cleland J, Fu M, Gheorghiade M, et al.
N Engl J Med
. 2018 Aug;
379(14):1332-1342.
PMID: 30146935
Background: Heart failure is associated with activation of thrombin-related pathways, which predicts a poor prognosis. We hypothesized that treatment with rivaroxaban, a factor Xa inhibitor, could reduce thrombin generation and...
10.
Chen S, Hellkamp A, Becker R, Berkowitz S, Breithardt G, Fox K, et al.
Am Heart J
. 2018 Jun;
200:102-109.
PMID: 29898836
Background: We investigated the impact of polyvascular disease in patients enrolled in ROCKET AF. Methods: Cox regression models were used to assess clinical outcomes and treatment effects of rivaroxaban compared...